Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-<i>κ</i>B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

<div>Proposal of a proinflammatory pathway inhibited by empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) in LPS-activated RAW 264.7 macrophages.</div>

Journal of Immunology Research

fig5

Figure 5

Figure 5: Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-<i>κ</i>B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways 

Figure 5 | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways 